Fused Azadecalin GR Modulators for Stronger Glucocorticoid Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new compositions and methods to modulate glucocorticoid receptors effectively, as existing agents like mifepristone have limitations in blocking the physiological effects of glucocorticoid receptor (GR) agonist binding.
Innovation Solution
Development of compounds such as ((4aR,8aS)-1-(4-fluorophenyl)-6-((2-methyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone and ((4aR,8aS)-1-(4-fluorophenyl)-6-((2-isopropyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(thiazol-4-yl)methanone, which act as GR modulators to antagonize or agonize the receptor, thereby treating associated disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing GR antagonists like mifepristone are used to block glucocorticoid receptor effects, then the ability to block GR agonist binding is improved, but therapeutic efficacy for various disorders is insufficient
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of GR modulators through systematic variations in molecular substituents (R1, R2, R3 groups) and core scaffold configurations. This results in compounds with optimized binding affinity and enhanced therapeutic efficacy for treating disorders such as obesity, hypertension, depression, and Cushing's syndrome, while maintaining reliable GR agonist binding blockade.
2Object-generated harmful factors
If new GR modulator compounds are developed to improve therapeutic efficacy, then treatment effectiveness for disorders is improved, but complexity of compound structure increases
Solution Approach 1:
The patent applies segmentation by dividing the GR modulator molecule into distinct functional segments: a core scaffold structure (pyrazolo[3,4-g]isoquinoline or similar fused ring systems) and variable substituent groups (R1, R2, R3). This modular approach allows systematic optimization of therapeutic efficacy while maintaining a manageable structural framework that facilitates synthesis and characterization.
Solution Approach 2:
The patent applies universality by designing a core scaffold structure that can accommodate multiple different substituent configurations while maintaining GR modulator activity. The fused ring system serves as a universal platform that supports various R1, R2, and R3 group combinations, enabling a single core structure to generate multiple compounds with different therapeutic profiles for various disorders.
Data Source
Figure 1
Figure 2~3
Figure 4
AI summary
The present invention provides octahydro fused azadecalin compounds having glucocorticoid receptor binding affinity and modulatory activity for pharmaceutical use. Also provided are pharmaceutical compositions containing an effective amount of the fused azadecalin compounds and methods of using the compositions for the-treatment of a glucocorticoid receptor mediated disorder in a subject.